BTLA (B and T lymphocyte associated) is a B cell and T cell attenuator, another checkpoint negative regulator of the Ig superfamily. It is structurally similar to CTLA-4 and PD-1, and is expressed in B cells, T cells, NK cells, dendritic cells and macrophages. BTLA binds to its ligand HVEM (a member of the tumor necrosis factor receptor superfamily) to transmit a co-inhibition signal. BTLA plays a negative regulatory role in the body's anti-tumor immune response, and is associated with the immune escape mechanism of the tumor. BTLA inhibitors enhance the TCR signaling pathway and restore T cell function, and become potential novel targets for tumor biotherapy.
mRNA expression verification:
Fig 1. Molecular identification of the B-hBTLA humanized mice. Mouse BTLA mRNA was detected in both the wild type and the B-hBTLA heterozygous mice, while human BTLA mRNA was detected only in the B-hBTLA heterozygous mice.
Protein expression verification:
Fig 2. Spleen cells from both wild type (WT) C57BL/6 and the B-hBTLA homozygous mice were analyzed by flow cytometry. Mouse BTLA+ B cells were detected in the WT mice, while human BTLA+ B cells were detected in the B-hBTLA homozygous mice.